What is Evommune?
Evommune is dedicated to pioneering novel therapies for chronic inflammatory diseases by targeting their fundamental biological drivers. Leveraging advanced immunology research, the company aims to develop treatments that offer more than just symptom management, focusing on improving patient outcomes in areas with limited existing options. The company's pipeline is strategically designed for conditions where current therapeutic approaches fall short, positioning Evommune at the forefront of innovation in the biotechnology sector.
How much funding has Evommune raised?
Evommune has raised a total of $185M across 3 funding rounds:
Angel/Seed
$12.5M
Series B
$57.5M
Series C
$115M
Angel/Seed (2020): $12.5M with participation from PIVOTAL BIOVENTURE PARTNERS LLC
Series B (2023): $57.5M led by Symbiosis Group, Arix Bioscience, and Verition Fund Management
Series C (2024): $115M supported by Avego, B Capital Group, Sectoral Asset Management, RA Capital Management, Longwood Fund, Amplitude Ventures, Pivotal Bioventure Partners, Andera Partners, Beiersdorf, ADAR1 Capital Management, RTW Investments, Marshall Wace, Verition Fund Management, and FemHealth Ventures
Key Investors in Evommune
Avego
Avego is a multi-strategy investment firm dedicated to the healthcare sector, aiming to combine industry expertise and capital with entrepreneurial management to enhance patient outcomes. The firm invests in both private and public companies innovating in healthcare, providing growth capital and focusing on mid-to-late stage venture opportunities.
B Capital Group
B Capital is a venture capital firm that focuses on empowering entrepreneurs by investing in early and late-stage companies within the Technology, Healthcare, and Climate sectors. With over $8 billion in assets under management, B Capital aims to support founders throughout the company-building lifecycle.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing drugs, medical devices, diagnostics, and research tools. Their mission is to partner with innovators to bring ideas from the lab to the clinic.
What's next for Evommune?
The recent major enterprise-level funding, particularly the Series C round, signals Evommune's transition into a scaling phase. This significant capital injection is expected to fuel the advancement of its clinical pipeline, potentially enabling the company to move promising drug candidates through later-stage trials and towards regulatory submission. The strategic backing from a diverse group of sophisticated investors, including those with deep expertise in healthcare and life sciences, suggests a clear path toward achieving key development milestones and potentially bringing impactful treatments to patients.
See full Evommune company page
